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Key Points
• SMAD1 is silenced by
hypermethylation in
DLBCL cell lines and
patient samples but not
in peripheral blood
B cells or lymph nodes.
•DAC treatment
restores SMAD1 ex-
pression and reverses
DLBCL growth in sev-
eral xenotransplanta-
tion and patient-derived
xenograft models.
The sphingosine-1-phosphate (S1P) receptor S1PR2 and its downstream adaptor Ga13 are
recurrently mutationally inactivated in the germinal center B-cell subtype of diffuse large
B-cell lymphoma (DLBCL) and are silenced by the S1PR2 repressor FOXP1 in the activated
B-cell like subtype of the disease. Loss of S1PR2 signaling relieves the germinal center
conﬁnement that is maintained by an S1P gradient and allows cells to resist S1P-induced
apoptosis. We have shown previously that S1PR2 expression is induced in normal B cells
through a newly described transforming growth factor-b (TGF-b)/TGF-bRII/SMAD1 signaling
axis that is inactivated in.85% of DLBCL patients. DLBCL cell lines lacking S1PR2, TGFBRII,
or SMAD1 as the result of genomic editing all have a strong growth advantage in vitro, as
well as in subcutaneous and orthotopic xenotransplantation models. Here, we show that the
TGF-b signaling pathway in DLBCL is blocked at the level of SMAD1 in DLBCL cell lines and
patient samples by hypermethylation of CpG-rich regions surrounding the SMAD1
transcription start site. The pharmacologic restoration of SMAD1 expression by the
demethylating agent decitabine (DAC) sensitizes cells to TGF-b–induced apoptosis and
reverses the growth of initially SMAD12 cell lines in ectopic and orthotopic models. This
effect of DAC is reduced in a SMAD1-knockout cell line. We further show that DAC restores
SMAD1 expression and reduces the tumor burden in a novel patient-derived orthotopic
xenograft model. The combined data lend further support to the concept of an altered
epigenome as a major driver of DLBCL pathogenesis.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults and is
characterized by substantial clinical and genetic heterogeneity. Comprehensive genetic analyses
that considered copy number variations, structural aberrations, point mutations and other genetic
abnormalities, transcriptional profiles, and clinical data from hundreds of patients have allowed the
stratification of DLBCL into 4 or 5 subtypes that differ in their cell of origin and associated transcriptional
signatures, mutational signatures, and clinical prognosis.1,2 These multiomics approaches have revealed
that classification into activated B-cell (ABC) and germinal center B-cell (GCB)–like subtypes of DLBCL
based on transcriptional signatures and cell of origin,3,4 which was the gold standard for.15 years, fails
to capture the clinical heterogeneity of the disease. In particular, the stratification of patients based on
co-occurring mutations has uncovered a previously unappreciated favorable-risk ABC DLBCL subtype
with genetic features of an extrafollicular, and possibly marginal zone, origin and has divided GCB
DLBCL into poor-risk (with structural aberrations in BCL2 and alterations of PTEN and epigenetic
enzymes) and good-risk categories, with distinct alterations in BCR/PI3K, JAK/STAT, and BRAF.1
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Despite these recent advances, very few genetic abnormalities are
likely to be exploited clinically in the near future. Among these are
inhibitors that interfere with chronic active B-cell receptor signaling
at the level of Bruton’s tyrosine kinase, which are projected to show
efficacy primarily in ABC DLBCL patients with co-occurring CD79
and MYD88 mutations2,5 and aberrations affecting Bcl-2 expres-
sion, which could potentially be targeted by BH3 mimetics, such as
venetoclax.6 In addition to the genetic diversity that is a hallmark of
DLBCL, aberrations of the epigenome are increasingly recognized
as a major driver of DLBCL pathogenesis. DLBCL cell lines and
primary samples differ substantially in terms of their global DNA
methylation and CpG island–specific DNA methylation profiles.7,8
Mutations in epigenetic modifiers are among the most commonly
occurring in both subtypes of DLBCL,9-11 and mutations in histone
acetyltransferase–encoding genes have been associated with espe-
cially poor outcomes.12,13 Because the repressive histone marks that
are affected by loss- or gain-of-function mutations in histone
methyltransferases (HMTs) and histone acetyltransferases (KMT2D,
EZH2, CREBBP, EP300) are directly linked to aberrant DNA
methylation,14-16 it is likely that the dysregulation of histone
modifications driven by some of these mutations affects (tumor
suppressor) gene expression.
We and other investigators have identified the G protein–coupled
receptor sphingosine-1-phosphate (S1P) receptor 2 (S1PR2) to be
recurrently inactivated or silenced in both cell-of-origin–derived
DLBCL subtypes. In GCB DLBCL, the genes encoding S1PR2 and
its downstream adaptor Ga13 (GNA13) are recurrently inactivated
by point mutations.17 In ABC DLBCL, the expression of S1PR2 is
silenced as a consequence of overexpression of its transcriptional
repressor FOXP1.18 Irrespective of subtype, the loss of S1PR2
signaling provides a major growth advantage to DLBCL cells in vitro
and in vivo: introducing the S1PR2-inactivating mutation by
CRISPR-mediated genome editing generates clones that grow
faster in vitro and that engraft and form ectopic and orthotopic
lymphomas more rapidly than the parental wild-type (WT) cell line.19
Conversely, the inducible expression of WT S1PR2, but not of
a point mutant incapable of activating downstream signaling
pathways, induces apoptosis in DLBCL cells and restricts tumor
growth in subcutaneous and orthotopic models of the disease.18 In
a genetically engineered mouse model of MYC-driven lymphoma,
the loss of S1pr2 accelerates spontaneous lymphomagenesis and
confers a growth advantage to serially transplanted lymphoma
cells.18,19 We reported recently that S1PR2 is negatively regulated
by FOXP1 and that the same regulatory elements of the S1PR2
gene are also bound by an activating transcription factor, SMAD1.19
Thus, optimal expression of S1PR2 occurs only if FOXP1 is absent
and SMAD1 is expressed, activated, and has translocated into the
nucleus. SMAD1 activation through its tyrosine phosphorylation
occurs as a consequence of transforming growth factor-b (TGF-b)
signaling. Indeed, the genetic deletion of SMAD1 or TGFBRII
phenocopies the effects of S1PR2 loss in vitro and in vivo in various
genetically modified and xenotransplantation models.19 We have
shown by immunohistochemical analysis of SMAD1 expression in 2
large DLBCL patient cohorts that the TGF-b/TGF-bRII/SMAD1 axis
is dysregulated at the level of SMAD1 expression, which is
aberrantly low in .85% of DLBCL patients.19 Here, we have
examined the mechanistic basis of SMAD1 silencing in DLBCL cell
lines and patient biopsies and show that the hypermethylation of 5
regions surrounding the SMAD1 transcription start site likely
accounts for the lack of SMAD1 expression that we observed in
the majority of cell lines and patient samples that were examined in
this study. The restoration of SMAD1 expression by the demethylat-
ing agent decitabine (DAC) rescues S1PR2 expression, as well as
sensitizes cells to TGF-b–induced apoptosis and reduces the
ectopic and orthotopic growth of DLBCL cell lines and primary cells
in vitro and in vivo.
Methods
Cell culture
The DLBCL cell lines used included 6 of the GCB DLBCL subtype
(SU-DHL-4, SU-DHL-5, SU-DHL-6, SU-DHL-8, SU-DHL-10, SU-DHL-
16), 4 of the ABC DLBCL subtype (U2932, OCI-Ly3, SU-DHL-2, and
RIVA), and 1 unclassified cell line (RC-K8). Selected cell lines were
subjected to various concentrations of DAC (Sigma-Aldrich) or
human TGF-b1 (referred to as TGF-b) (PeproTech). DAC-treated
cells were analyzed with respect to SMAD1 and S1PR2 expression
by quantitative reverse-transcription polymerase chain reaction
(qRT-PCR), apoptosis by annexin V staining, and SMAD1 protein
expression by western blot. Cell lines were labeled with luciferase
via lentiviral transfer and subjected to SMAD1 deletion via CRISPR/
Cas9 manipulation; they were also subjected to bisulfite sequencing
of the SMAD1 promoter region. Culture conditions, treatment
conditions, apoptosis assays, RNA extraction and qRT-PCR,
western blotting technique, lentiviral gene transfer, SMAD1
CRISPR manipulations, and bisulfite sequencing are described
in supplemental Material and methods.
Animal experimentation
NOD/SCID/IL2Rg2/2 (NSG) mice, CSFh;IL-3/GM-CSFh;hSIR-
PAtg;TPOh;Rag22;gc2 (MISTRG) mice, and CSFh;IL-3/GM-
CSFh;hSIRPAtg;TPOh;Rag22;gc2;IL6h (MISTRG6) mice11 were
obtained from a local repository. For xenotransplantation studies,
RC-K8 or SU-DHL-4 cells (203 106 or 103 106 cells, respectively,
in 200 mL of phosphate-buffered saline [PBS]) were injected
subcutaneously into both flanks of 6- to 8-week-old NSG mice.
Once palpable tumors had formed in the subcutaneous model, the
volume of the tumors was measured by calipers and calculated using
the formula (A2 3 B)/2, where A is the shorter tumor dimension
and B is the longer tumor dimension. From day 12, mice were injected
intraperitoneally with 0.25 or 0.5 mg/kg 5-aza-29-deoxycytidine
(referred to as DAC, reconstituted in PBS; Sigma-Aldrich) or PBS
as control for 5 consecutive days per week for 2 weeks. For orthotopic
in vivo imaging system (IVIS) studies, 10 3 106 luciferase-labeled
RC-K8, SU-DHL-6, or SU-DHL-4 cells were injected IV in a volume
of 100 mL into 6- to 8-week-old MISTRG or MISTRG6 mice11 to
evaluate orthotopic growth. Mice were imaged once a week to
determine the dissemination of cells. For DAC treatment studies,
after 2 to 3 weeks, when engrafted cells could be detected in all
experimental animals, mice were injected intraperitoneally with
0.25 mg/kg DAC or PBS as control for 5 consecutive days per
week for 3 weeks. For the patient-derived xenograft transplanta-
tion model, bone marrow mononuclear cells containing DLBCL
cells (obtained from the Clinic of Hematology-Oncology, Univer-
sity of Zurich) from a consenting patient with stage IVBE ABC
DLBCL with extranodal manifestations in the liver and;7% tumor
cell infiltration of the marrow, who was selected because of
aberrantly high SMAD1 methylation in the tumor cells, were
injected IV into MISTRG6 mice. A total of 1.5 3 106 lymphoma
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cells that had engrafted in the spleen was serially transplanted into
MISTRG6 mice, and mice were treated 2 weeks after injection
with 0.25 mg/kg DAC or PBS as control for 5 consecutive days
per week for 3 weeks. At the end point, spleen and bone marrow
cells were subjected to fluorescence-activated cell sorting
(FACS) analysis of CD451 cells. FACS analysis is described in
supplemental Material and methods. All animal studies were
reviewed and approved by the Zurich Cantonal Veterinary Office
(licenses 227/2015, 235/2015). Ethical approval for work with
primary DLBCL cells was obtained from the Ethical Commission of
the Canton of Zurich (KEK-ZH No. 2009-0062/1).
SMAD1 immunohistochemistry on patient samples
and SMAD1 immunofluorescence microscopy of
cell lines
Expression of SMAD1 was studied by immunohistochemistry on 6
DLBCL patient samples (3 nodal, 1 lung, and 2 testicular). Of the
3 nodal samples, 1 was classified as GCB and 2 were classified
as non-GCB, according to the Hans classification that takes
CD10, BCL-6, and MUM1 expression into account and is ;80%
accurate in stratifying DLBCL into GCB and non-GCB subsets.20
The 2 testis DLBCL samples were classified as non-GCB, with 1
exhibiting a BCL-6 rearrangement and the other exhibiting KMT2D
and PIM1 mutations. The lung DLBCL case was also non-GCB.
The primary polyclonal antibody (cs9743; Cell Signaling Technol-
ogy) was diluted 1:40 and incubated for 20 minutes in an
automated immunostainer (BenchMark; VENTANA/Roche) after
heat-induced antigen retrieval with CC1 buffer for 40 minutes.
DNA was extracted from the same samples and subjected to
bisulfite sequencing. Bisulfite sequencing is described in supple-
mental Material and methods. For SMAD1 immunofluorescence
microscopy, cells were fixed for 15 minutes in 4% paraformalde-
hyde, permeabilized for 5 minutes in 1% NP-40, and stained for
90 minutes in the same primary antibody (1:40 dilution; cs9743;
Cell Signaling Technology) as used for immunohistochemistry,
followed by labeling with goat anti-rabbit secondary antibody (Life
Technologies; 1:200 dilution) for 60 minutes. Images were
acquired with a Leica DM6B fluorescence microscope.
Statistics
All statistical analyses were performed using GraphPad Prism
software. Graphs represent mean plus standard error of the mean
(SEM) for$3 independent experiments for cell culture experiments
and medians for mouse experiments, unless indicated otherwise in
the figure legend. Statistical analysis was performed using a 2-tailed
Student t test for in vitro assays and a 2-tailed Mann-Whitney U test
for in vivo studies.
Results
SMAD1 is silenced by DNA methylation of its
promoter region in the majority of DLBCL cell lines
and primary human DLBCL
Having reported previously that SMAD1 is aberrantly silenced in
.85% of 259 examined DLBCL patients,19 we queried the publicly
available Cancer Cell Line Encyclopedia (CCLE) database for more
evidence. Of the 1457 cell lines from ;40 tumor entities for which
transcriptomic data based on RNA sequencing were available, the
18 DLBCL cell lines showed the lowest mean expression of
SMAD1 (Figure 1A). Interestingly, the same 18 cell lines showed
the highest level of SMAD1 methylation (Figure 1B); SMAD1
expression and methylation of the SMAD1 locus were strongly
inversely correlated in these 18 cell lines (Figure 1C). Two other
SMAD proteins with strong homology to SMAD1, which have
been implicated as acting in concert with SMAD1 to transactivate
target genes of the TGF-b signaling pathway, were strongly
expressed across all cell lines with no evidence of DNA methylation
(SMAD5) or were not expressed, but inconspicuous, relative to
other tumor entities (SMAD9; supplemental Figure 1A-D). Other
common types of lymphoma (Burkitt, Hodgkin) showed very different
SMAD1 expression and methylation patterns, with generally higher
SMAD1 expression and less evidence for methylation (supplemental
Figure 1A-D).
We next experimentally addressed a possible inverse correlation
between SMAD1 expression and SMAD1 methylation in a panel of
11 DLBCL cell lines covering GCB and ABC subtypes. Only 1 of
the 11 cell lines showed evidence of SMAD1 expression, as
determined by western blotting (Figure 1D). Interestingly, bisulfite
sequencing of 5 regions enriched for CG dinucleotides in the
SMAD1 promoter (supplemental Figure 1F) that had previously
been identified as being subject to hypermethylation21 revealed
that the SMAD11 cell line SU-DHL-6 exhibited a lower mean
methylation level compared with 3 SMAD12 cell lines across
these 5 regions (Figure 1E). Regions 2 and 4 differed most
markedly in terms of their methylation (Figure 1E). We next
assessed SMAD1 expression and SMAD1 methylation status of 6
primary patient cases of DLBCL from various sites (testis, lung,
lymph nodes) by immunohistochemistry and bisulfite sequencing,
respectively. All 6 DLBCL cases (1 was classified as GCB and 5
were classified as a non-GCB subtype according to the Hans
algorithm)20 were negative for SMAD1 (representative photo-
micrographs, Figure 2A), irrespective of their tissue of origin, and
they exhibited strong methylation of region 2 (Figure 2B) and of
the other 4 regions examined (supplemental Figure 2A). Two
marginal zone B-cell lymphomas of the stomach that were
analyzed alongside the DLBCL cases showed similar methylation
patterns as the DLBCL cases; in contrast, the SMAD1 promoter
region 2 of immunomagnetically isolated B cells from donor blood
was unmethylated, as was region 2 in 3 normal lymph node
samples (Figure 2B). The other regions differed less with regard to
their methylation status (supplemental Figure 2A). GCB cells in
lymph node sections were positive for SMAD1, as judged by
immunohistochemistry (Figure 2A), as were normal B cells, as
determined by western blotting (supplemental Figure 2B). The
combined observations obtained by immunohistochemistry of
259 patients, as reported previously,19 by mining of the CCLE
database for paired methylation and expression data for all
available DLBCL and Hodgkin and Burkitt lymphoma cell lines,
and by methylation and expression analyses of 6 primary DLBCL
samples, several cell lines, and normal control samples suggest
that SMAD1 is recurrently silenced by methylation of its promoter
region in DLBCL but not in other lymphomas or normal B cells.
SMAD1 expression and susceptibility to
TGF-b–induced apoptosis are restored by
DAC treatment
We next addressed whether the inhibition of de novo DNAmethylation
by exposure to the cytidine analog DAC, which efficiently inhibits the
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Figure 1. SMAD1 is silenced by DNA methylation of its promoter region in the majority of DLBCL cell lines. In silico analysis of ;1000 cell lines of the various
indicated origins that are publicly available through the CCLE database with respect to SMAD1 expression (A) and SMAD1 gene methylation (B). DLBCL cell lines are
highlighted in red. (C) Correlation between SMAD1 expression and gene methylation in DLBCL cell lines in the CCLE database. (D) SMAD1 expression, as determined by
western blotting of a panel of DLBCL cell lines. ABC DLBCL cell lines are in blue, and GCB DLBCL cell lines are in green. The classification of RC-K8 is controversial. Tubulin
serves as loading control. (E) Methylation analysis by bisulfite sequencing of 5 regions of the SMAD1 promoter in SMAD1-expressing (SU-DHL-6) vs SMAD12 (RC-K8,
SU-DHL-4, RIVA) cell lines, as determined by bisulfite sequencing. Each circle represents 1 CG dinucleotide. Each line represents 1 clone. Two to 4 clones were sequenced
per sample. d, methylated cytosine; O, unmethylated cytosine; 3, aligned mismatches between genomic and bisulfite sequences.
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methyltransferase DNMT3, would restore SMAD1 expression in
SMAD12 DLBCL cell lines. Indeed, 4 days of exposure were
sufficient to restore SMAD1 transcription and protein expression in
a subset of our initially SMAD12 cell lines to roughly the level
observed in the SMAD11 cell line SU-DHL-6, as determined by
qRT-PCR and western blotting (Figure 3A-B). SMAD11 SU-DHL-6
cells did not respond to DAC with (even) higher SMAD1 expression
(Figure 3A-B). Other cell lines that were initially SMAD12 failed to
respond to DAC with SMAD1 reactivation, as judged by qRT-PCR
and western blotting (supplemental Figure 3A-B). In those cell lines
that responded to DAC, increased SMAD1 expression correlated
with increased expression of the recently identified SMAD1 target
S1PR2 (Figure 3C); in contrast, only 1 of the 4 cell lines that failed
to upregulate SMAD1 at the protein level upon DAC exposure
exhibited increased expression of S1PR2 (supplemental Figure 3C).
Interestingly, genomic editing of the first exon of SMAD1 in 1 of the
DAC-responsive cell lines, SU-DHL-4, abrogated the reactivation of
SMAD1 upon DAC exposure (Figure 3D; supplemental Figure 3D),
as well as the induction of S1PR2 expression upon treatment with
DAC, especially in combination with the S1PR2 inducer TGF-b
(Figure 3E). Because we had previously shown that S1PR2
expression induced by TGF-b signaling promotes DLBCL
apoptosis, we subjected the SMAD12 and DAC-responsive cell
lines RIVA, SU-DHL-4, and RC-K8 to DAC treatment, with and
without additional exposure to TGF-b; the SMAD11 cell line SU-
DHL-6 served as control. As reported, TGF-b robustly induced
S1PR2 expression,19 which was further enhanced by prior DNA
demethylation in all SMAD12 cell lines, but not in the SMAD11
cell line SU-DHL-6 (supplemental Figure 3E), and coincided with
apoptosis induction, as determined by annexin V staining (supple-
mental Figure 3F). TGF-b–induced apoptosis was enhanced by prior
DNA demethylation in DAC-responsive cell lines, as well as in SU-
DHL-6 cells, which constitutively express SMAD1, indicating that
the SMAD1/S1PR2 axis represents 1 of multiple pathways to
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Figure 2. DLBCL patient samples exhibit low SMAD1
expression and high SMAD1 promoter hypermethylation.
(A) Immunohistochemical SMAD1 staining of DLBCL patient
samples derived from testis, lung, and lymph nodes, as well as
a gastric marginal zone lymphoma (MZL) sample. Normal lymph
nodes are shown as control. Scale bars, 100 mm. (B)
Methylation analysis by bisulfite sequencing of region 2 within
the SMAD1 promoter in DLBCL, MZL, normal B-cell, and lymph
node samples. Each circle represents 1 CG dinucleotide. Each
line represents 1 clone. Two or 3 clones were sequenced per
sample. d, methylated cytosine; O, unmethylated cytosine; 3,
aligned mismatches between genomic and bisulfite sequences.
The red asterisk marks the patient sample that was further used
for patient-derived xenotransplantation experiments in Figure 6.
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TGF-b–induced cell death (supplemental Figure 3F). This observation
was confirmed in SMAD1-knockout (SMAD1KO) SU-DHL-4 cells,
which were killed effectively in vitro by combinedDAC/TGF-b exposure,
despite failing to express SMAD1 and S1PR2 (Figure 3D-E;
supplemental Figure 3G). The combined results suggest that SMAD1 is
epigenetically silenced by DNA methylation in a subset of DLBCL cell
lines, which favors cell survival in the presence of TGF-b; this aberrant
regulation can be reversed by pharmacological DNA demethylation.
DAC treatment decreases the tumor burden in vivo in
subcutaneous and orthotopic models of DLBCL
We have previously reported that clones of the SMAD1-expressing
cell line SU-DHL-6 that have been genome edited to knock out
SMAD1 engraft better in the spleen and bone marrow of
humanized mice than do WT clones.19 The mouse strain that
served as host strain for orthotopic growth was generated on the
Rag22/2IL2Rg2/2 background, and it expresses the human
cytokines macrophage colony-stimulating factor, interleukin-3,
thrombopoietin, and granulocyte-macrophage colony-stimulating
factor, as well as SIRP1a from the respective murine loci
(MISTRG).13 This in vivo orthotopic growth advantage of SMAD1KO
SU-DHL-6 clones in MISTRG mice could be confirmed by
comparative IVIS of WT SMAD1 (SMAD1WT) and SMAD1KO
clones that had been lentivirally transduced with a luciferase
expression construct (supplemental Figure 4A-C). To determine
whether the restoration of SMAD1 expression that can be achieved
by DAC treatment in vitro (Figure 3A-B) would reduce tumor growth
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in vivo, we subcutaneously transplanted the SMAD12 cell lines RC-
K8 and SU-DHL-4 onto the flanks of NSG mice. DAC treatment
significantly reduced, and even reversed, tumor growth over time in
both cell lines when administered at 2 concentrations in a thera-
peutic setting (ie, once tumors were palpable) (Figure 4A-D). Tumor
size and volume were significantly lower in DAC-treated mice at the
study end point (Figure 4B,D). To be able to investigate the effects
of DAC in an orthotopic model, we took advantage of MISTRG and
MISTRG6 mice, which differ from the parental MISTRG strain in
their additional expression of human interleukin-6 from a knock-in
allele.14 Although MISTRG mice efficiently supported the ortho-
topic engraftment of SU-DHL-4 cells (delivered IV), we had to resort
to MISTRG6 mice for the orthotopic (IV) xenotransplantation of RC-
K8 cells. Their luciferase expression allowed for the visualization and
detection of SU-DHL-4 and RC-K8 cells by IVIS in the hip and leg
bones as early as 2 weeks postinjection (Figure 4E; supplemental
Figure 4D-E). In vehicle-treated mice, the tumor burden increased
over time as cells spread to various internal organs over the 5-week
(RC-K8) to 6-week (SU-DHL-4) time course; mice began to
develop symptoms, such as weight loss and hind leg paralysis, at
;30 days posttumor cell injection (Figure 4E-G; supplemental
Figure 4D-F). The development of clinical symptoms correlated well
with a particularly high tumor burden, as determined by IVIS. In
contrast, mice that had been administered daily doses of DAC
starting at 14 days posttumor cell injection exhibited a stabilization
of their tumor burden and did not develop overt disease symptoms
(Figure 4E-G; supplemental Figure 4D-F). The combined results
indicate that DAC reduces and reverses the growth of established
DLBCL cell lines with aberrantly low or absent SMAD1 expression
resulting from promoter hypermethylation in ectopic and orthotopic
models.
The success of DAC treatment requires SMAD1
reactivation in vivo in subcutaneous and
orthotopic models
To examine whether the beneficial effects of DAC treatment in vivo
require SMAD1, we compared SMAD1-proficient and SMAD1-
deficient SU-DHL-4 cells in terms of their growth kinetics in the
subcutaneous tumor model described in Figure 4. To this end, NSG
mice were subcutaneously transplanted with SMAD1WT and
SMAD1KO SU-DHL-4 cells in their left and right flanks, respectively,
and subjected to DAC or vehicle treatment once tumors were
palpable. Although SMAD1WT cells showed the usual rapid
response to DAC that is characterized by slowing of tumor growth
and tumor regression, this was not the case with SMAD1KO cells
(Figure 5A-B). Similar observations were made in the orthotopic
model, as determined by IVIS measurements over time (Figure 5C-D)
and by monitoring disease symptoms (weight loss, hind leg paralysis)
over time (Figure 5E). The combined results indicate that the
therapeutic success of DAC requires a functional SMAD1 locus and
rules out a major contribution of other differentially methylated genes
to tumor suppression induced by demethylating agents.
Primary DLBCL cells with low SMAD1 expression and
high SMAD1 promoter hypermethylation engraft in
MISTRG6 mice and are responsive to DAC treatment
Because MISTRG6 mice support the orthotopic growth of DLBCL
cell lines, we speculated that the same strain might also allow us to
develop a patient-derived xenograft model that would lend itself to
preclinical testing of DAC efficacy. We obtained live cells from
a bone marrow biopsy from a patient with stage IVBE ABC
DLBCL with extranodal manifestations in the liver, an International
Prognostic Index score of 5, splenomegaly, and ;7% tumor cell
infiltration of the marrow that exhibited high SMAD1 methylation in
4 of the 5 investigated regions (Figure 2B; supplemental Figure 2A,
marked by an asterisk) and no detectable SMAD1 or S1PR2
expression at the RNA level (Figure 6A). All available viable tumor
cells (100 000) were injected IV into a MISTRG6 recipient, where
they engrafted in the bone marrow and spleen within 6 weeks.
Spleen cells from this mouse were serially transplanted IV into larger
cohorts of MISTRG6 mice and subjected to daily DAC or vehicle
(PBS) treatment throughout the 5-week course of the experiment.
The serially transplanted primary DLBCL cells formed splenic
lymphomaswith bonemarrow involvement that were highly responsive
to DAC treatment, as judged by flow cytometric quantification of
human cells in the spleen and bone marrow, as well as by determining
spleen weights at the study end point (Figure 6B-E). Cells residing in
the bone marrow were more resistant to DAC than were those in the
spleen (Figure 6B-D). Spleens of mice that had been subjected to
DAC treatment exhibited less tumor cell infiltration, as judged by
histology (Figure 6F), and a generally stronger SMAD1 signal
(Figure 6G). The combined results suggest that primary DLBCL
cells can engraft in the spleen and bone marrow of MISTRG6
mice and that DAC treatment reduces the tumor burden associ-
ated with primary DLBCL xenotransplantation in this model.
Discussion
Genes encoding epigenetic modifiers, and especially those
encoding histone-modifying enzymes, such as HMTs or histone
acetyltransferases, are among the most recurrently mutated genes
in DLBCL,11 and perturbations of the epigenome are increasingly
recognized as a driving force in DLBCL pathogenesis.22 Both main
subtypes of DLBCL are commonly affected by loss-of-function
mutations of the HMT KMT2D, gain-of-function mutations of
the HMT EZH2, and loss-of-function mutations of the histone
acetyltransferases CREBBP and EP300, which together occur in
;50% of DLBCL patients.11 Mutations in epigenetic modifiers are
believed to be founder events that predispose normal B cells to
malignant transformation.22 In the panel of 11 cell lines investigated
in this study with respect to SMAD1 methylation and expression,
mutations in the 4 above-mentioned genes were even more
common than in published patient cohorts, with CREBBP/EP300
mutations together affecting 9 of 11 cell lines23 and EZH2/KMT2D
mutations affecting 4 of 11 cell lines.24 Repressive histone marks,
and especially the polycomb-mediated methylation on Lys27 of
histone H3, have been directly linked to aberrant hypermethylation
of CpG islands in cancer cells.14-16 We and other investigators
have performed genome-wide DNA methylation profiling of DLBCL
cell lines and primary patient material, which has led to the
identification of numerous genes that are aberrantly silenced in
both subtypes of DLBCL.7,8 Examples of tumor-suppressor genes
known to be silenced by promoter hypermethylation in DLBCL
include DUSP4, MGMT, CDKN2A, and the lamin A/C gene.7,25-27
Epigenetic heterogeneity has emerged as an important hallmark of
DLBCL, and a high degree of inter- and intratumoral heterogeneity
has been associated directly with disease aggressiveness, likeli-
hood of relapse, and inferior patient survival.28-30
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Figure 4. DAC treatment decreases tumor burden in vivo in a subcutaneous and in a novel orthotopic model of DLBCL RC-K8 (A-B) and SU-DHL-4 (C-D)
DLBCL cell lines were subcutaneously injected into the flanks of NSG mice. From day 12 after transplantation, mice were treated systemically with 0.25 mg/kg or 0.5 mg/kg
DAC for 2 cycles, 5 days per week. Tumor volume was measured continuously (A,C), and tumor weight was measured at the end point (B,D). (B,D) Because of the toxicity of
the 0.5-mg/kg treatment, only 4 of 12 mice and 8 of 12 mice are represented for RC-K8 and SU-DHL-4, respectively, at the end point. Graphs in panels A and C show mean
6 SEM; in panels B and D, median values are presented as horizontal lines. Graphs represent pooled data from 2 independent experiments. The P values were calculated
using the Mann-Whitney U test. (E-G) RC-K8 cells were subjected to lentiviral gene transfer of luciferase and injected IV into MISTRG6 mice. Mice were treated with 0 or
0.25 mg/kg DAC starting from day 19 after injection. Representative IVIS images of mice (E) and the radiance over 5 weeks (F) are shown. Results in panel F are from
1 experiment and representative of 2 independent ones. (G) Survival curve showing the percentage of injected mice without symptoms of disease (paralysis, weight loss); the
P value was calculated using the log-rank (Mantel-Cox) test. Data are pooled from 2 independent experiments. *P , .05, **P , .01, ***P , .001, ****P , .0001. n.s., not
significant.
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Here, we provide experimental evidence for aberrant silencing
of SMAD1 by hypermethylation of 5 regions that are up- and
downstream of the transcription start site; these SMAD1 sites were
previously identified in a study alongside 8 other loci as being
recurrently hypermethylated in chemoresistant DLBCL and as
being functionally required for chemosensitization.21 One region,
region 2, emerges from our analyses as possibly being more
relevant than the other 4 in directing SMAD1 expression. Our data
suggest that SMAD1 is not hypermethylated solely as a conse-
quence of exposure to chemotherapy; rather, data obtained from
patient samples taken at diagnosis indicate that SMAD1 silencing
by promoter hypermethylation is a common, and probably early,
event in DLBCL pathogenesis. We have previously examined the
expression of SMAD1 by immunohistochemistry in 2 large patient
cohorts and found that only 7 of 75 patients in 1 cohort (9.3%) and
29 of 184 patients in the other cohort (15.7%) had tumor cells that
expressed SMAD1 (range, 10%-90% of tumor cells being positive),
whereas B cells from peripheral blood or GCB cells in normal
tonsils were invariably positive for SMAD1.19 The fraction of
SMAD11 cases was equally low in patients with GCB (15%) or
ABC (13%) DLBCL subtypes, indicating that SMAD1 is selectively
downregulated, irrespective of the subtype.19 Our data contrast to
some degree with another survey of SMAD1 expression that also
used immunohistochemistry of tissue microarrays but was con-
ducted with an antibody specific for the phosphorylated forms of
SMAD1 and SMAD5.21 This study concluded that the majority
(70%) of the examined 248 DLBCL cases showed phospho-SMAD
expression in $20% of the tumor cells.21 The different specificities
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Figure 5. A functional SMAD1 locus is re-
quired for the therapeutic efficacy of DAC
treatment. (A-B) SMAD1WT and SMAD1KO SU-
DHL-4 cells were injected subcutaneously into the
flanks of NSG mice. From day 12 after transplanta-
tion, mice were treated systemically with 0.25 mg/kg
DAC for 2 cycles, 5 days per week. The tumor
volume was measured continuously (A), and tumor
weights were recorded at the end point (B). Data in
panels A-B are pooled from 2 independent studies,
and P values were calculated using the
Mann-Whitney U test (for every time point relative
to the red curve in panel A). (C-E) SMAD1WT and
SMAD1KO SU-DHL-4 cells were subjected to lenti-
viral gene transfer of luciferase and injected IV into
MISTRG mice. Mice were treated with 0 or
0.25 mg/kg DAC starting from day 15 after in-
jection. IVIS images of all included mice (C) and the
radiance over 5 weeks (D) are shown. (D) P values
were calculated using the Mann-Whitney U test (for
every time point relative to the red curve). (E)
Survival curve showing the percentage of injected
mice without symptoms of disease (paralysis,
weight loss). The log-rank (Mantel-Cox) test was
used for statistical comparisons. Data in panels C-E
are pooled from 2 studies; the scale marked with
a red asterisk (*) (far right panel in panel C) applies
to the mice denoted by the asterisk (*) in panel C.
Differences in panels D-E show trends only; 1
mouse (KO, on DAC) died from its disease before
the study end point, and 1 mouse (WT, on DAC)
died from nondisease-related causes. *P , .05,
**P , .01, ***P , .001.
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of the antibodies used likely account for the observed differences in
SMAD1 expression/phosphorylation in the 2 datasets. Bisulfite
sequencing is labor intensive and cannot readily be scaled up to
examine large numbers of patients; however, the small number of
patients for whom both high-quality DNA (for SMAD1 bisulfite
sequencing) and histological sections (for SMAD1 immunohisto-
chemistry) were available suggests that aberrant SMAD1 silencing
is attributable to SMAD1 hypermethylation. This was also confirmed
in in silico analyses of 18 DLBCL cell lines included in the CCLE
database and in our own panel of DLBCL cell lines. In contrast, in
the above-mentioned study published by Clozel et al,21 the
frequency of SMAD1-hypermethylated cases was found to be
substantially lower (75% of patients with DLBCL showed #5%
SMAD1 methylation) than in our small patient cohort available for
methylation and expression analysis; furthermore, the investiga-
tors found a clear bias of SMAD1 methylation toward the ABC
DLBCL subtype in their cohort. Because our small patient
selection was strongly biased toward ABC DLBCL, we may be
overestimating the role of SMAD1 methylation in the silencing of
the locus.
SMAD1 relays signals downstream of the TGF-b receptor and
becomes phosphorylated upon ligand binding. Among the target
genes of the TGF-bRII/SMAD1 axis is the gene encoding the G
protein–coupled receptor S1PR2, which we have recently identi-
fied by chromatin immunoprecipitation.19 The genes encoding
S1PR2 and its downstream adaptor protein Ga13, GNA13, are
known to be recurrently mutated in the GCB subtype of DLBCL.17
In contrast, in ABC DLBCL, the expression of S1PR2 is silenced by
overexpression of FOXP1, a transcriptional repressor of S1PR2
that binds to 2 genomic loci that overlap with the SMAD1 binding
sites in the 5-kb regulatory region upstream of the S1PR2
transcription start site.18 The new data presented here show that,
in most cases of DLBCL, an additional epigenetic layer of
regulation is in place that prevents S1PR2 expression (Figure 7).
The mechanistic basis for the tumor-suppressive properties of
S1PR2 and its Ga13-driven downstream signaling pathway are not
fully understood, although gain-of-function and loss-of-function
experiments have confirmed their critical contribution to DLBCL
pathogenesis. Evidence for this has come from xenotransplantation
settings, in which the loss of S1PR2 contributes to tumor growth in
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Figure 6. SMAD12DLBCL patient cells re-
spond to DAC treatment in a patient-derived
xenograft model. (A) SMAD1 and S1PR2 ex-
pression in CD191 primary DLBCL cells, as de-
termined by qRT-PCR; SU-DHL-6 cells are shown
as positive control. Percentages of human CD451
cells in the spleen (B) and bone marrow (C) of
MISTRG6 mice that were injected with primary
DLBCL cells and treated with 0.25 mg/kg DAC for
3 cycles of 5 days per week. (D) Spleen weights at
the end point. (E) Representative FACS plots
showing frequencies of human and mouse CD451
cells in the spleens. In panels B-D, each symbol
represents 1 mouse and horizontal lines represent
median values; data are pooled from 3 in-
dependent experiments. (F) Hematoxylin and
eosin–stained sections of spleens from representa-
tive mice treated or not with DAC. Scale bars,
100 mm. (G) SMAD1 immunohistochemical stain-
ing of representative mice treated or not with DAC.
Scale bars, 100 mm. *P , .05, **P , .01,
Mann-Whitney U test. n.d., not detectable.
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ectopic and orthotopic models, as well as from models of MYC-
driven lymphomagenesis, which is accelerated in mice that are
deficient for S1pr2.18,19
Our results provide experimental evidence from ectopic and
orthotopic xenotransplantation models, using cell lines and primary
cells, that DAC or other inhibitors of de novo DNAmethylation might
be beneficial in DLBCL, especially in patients with low or no
SMAD1 expression. Similar effects have been shown previously for
the relatively chemoresistant DLBCL cell line Oci-Ly7; DAC alone,
and especially in synergy with doxorubicin, reduced subcutaneous
tumor growth.21 Another study by Kalac et al, using the cell line Oci-
Ly1 in a subcutaneous model, found strong effects of DAC only in
combination with the histone deacetylase inhibitor panobinostat.31
DAC and its analog azacitidine are approved for the treatment of
myelodysplastic syndromes and acute myeloid leukemias. Both
compounds are comparatively well tolerated, and as monotherapy
they yield response rates from 10% to 50% in these 2 indications;
however, they are not curative.32,33 The recent addition of the Bcl-2
inhibitor venetoclax to DAC or azacitidine increased complete
remission rates for acute myeloid leukemias in the high-risk elderly
to .60%.34 Azacitidine priming, followed by standard chemo-
immunotherapy, in 10 high-risk patients with newly diagnosed
DLBCL has already shown some promise in a phase I clinical trial.21
Our data indicate that this strategy deserves further attention, and
we propose loss of SMAD1 expression as a potentially useful
biomarker in rationally guiding treatment decisions. Our results
further highlight the value of MISTRG and MISTRG6 mice as host
strains for pre- or coclinical testing of novel drugs or of drug
combinations. We show here that primary DLBCL cells can be
expanded and serially passaged in MISTRG6 mice to generate
a disease model that offers a window of opportunity for therapeutic
testing of ;4 to 6 weeks. Our immunohistochemical staining
suggests that SMAD1 expression is at least partially restored by
DAC treatment in the primary xenotransplantation setting, providing
the first hints that the success of this treatment may be linked to
SMAD1 restoration. The combined results lend further support to
the concept that epigenetic modifications leading to aberrant
silencing of key tumor suppressors in DLBCL can be targeted
pharmacologically with approved and well-tolerated agents.
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Figure 7. Schematic summary of the dysregulation of
SMAD1 expression by promoter hypermethylation and
the consequences for DLBCL survival and growth. In
both subtypes of DLBCL, the promoter region of SMAD1 is
recurrently hypermethylated, which causes SMAD1 gene
repression. Repression of SMAD1 blocks the tumor-
suppressive TGF-b/SMAD1/S1PR2 pathway. Loss of S1PR2
expression within the germinal center promotes B-cell pro-
liferation and prevents S1P-driven apoptosis. DAC demethy-
lates SMAD1 and restores SMAD1 expression, allowing its
phosphorylation upon TGF-b binding and its translocation in-
to the nucleus, followed by S1PR2 expression, as well as
a reduction in the tumor burden in experimental settings.
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